Pertento Partners LLP Raises Holdings in Cellebrite DI Ltd. $CLBT

Key Points

• Pertento Partners LLP increased its stake in Cellebrite DI (CLBT) by 57.8% in Q3 to 4,648,215 shares, making CLBT 10.0% of the fund's portfolio and its third-largest holding (about 1.94% of the company, valued at $86.13M).
• Cellebrite reported quarterly EPS of $0.14 (in line) and revenue of $128.82M (up 28.8% YoY and above estimates); the stock trades around $14.49 with a $3.61B market cap and a consensus "Moderate Buy" price target of $22.50.

Pertento Partners LLP increased its stake in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 57.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,648,215 shares of the company's stock after purchasing an additional 1,702,574 shares during the period. Cellebrite DI accounts for 10.0% of Pertento Partners LLP's portfolio, making the stock its 3rd largest position. Pertento Partners LLP owned approximately 1.94% of Cellebrite DI worth $86,131,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in CLBT. Voss Capital LP increased its position in Cellebrite DI by 34.0% in the 2nd quarter. Voss Capital LP now owns 5,150,000 shares of the company's stock valued at $82,400,000 after acquiring an additional 1,306,398 shares during the period. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of Cellebrite DI in the third quarter worth $19,457,000. Handelsbanken Fonder AB increased its holdings in shares of Cellebrite DI by 61.3% during the second quarter. Handelsbanken Fonder AB now owns 2,450,000 shares of the company's stock valued at $39,200,000 after purchasing an additional 931,300 shares during the period. Thematics Asset Management bought a new stake in shares of Cellebrite DI during the second quarter valued at about $13,919,000. Finally, Qube Research & Technologies Ltd raised its stake in shares of Cellebrite DI by 93.7% during the second quarter. Qube Research & Technologies Ltd now owns 1,500,505 shares of the company's stock valued at $24,008,000 after purchasing an additional 725,679 shares in the last quarter. Institutional investors own 45.88% of the company's stock.

Cellebrite DI Stock Down 1.4%

Shares of NASDAQ CLBT opened at $14.49 on Thursday. Cellebrite DI Ltd. has a 52-week low of $11.76 and a 52-week high of $20.86. The stock has a market capitalization of $3.61 billion, a price-to-earnings ratio of 46.74, a PEG ratio of 2.25 and a beta of 1.30. The stock's fifty day simple moving average is $15.41 and its 200 day simple moving average is $16.92.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share for the quarter, meeting analysts' consensus estimates of $0.14. The business had revenue of $128.82 million during the quarter, compared to analyst estimates of $126.07 million. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.Cellebrite DI's revenue for the quarter was up 28.8% on a year-over-year basis. During the same quarter last year, the company posted $0.10 EPS. As a group, analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Bank of America raised their target price on shares of Cellebrite DI from $24.00 to $25.00 and gave the company a "buy" rating in a research note on Thursday, November 13th. Needham & Company LLC reduced their price target on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, February 12th. Lake Street Capital increased their price objective on shares of Cellebrite DI from $22.00 to $23.00 and gave the company a "buy" rating in a report on Thursday, November 13th. JPMorgan Chase & Co. raised their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the company an "overweight" rating in a research note on Thursday, November 13th. Finally, Wall Street Zen cut Cellebrite DI from a "hold" rating to a "sell" rating in a research note on Saturday, March 7th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $22.50.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company's technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company's flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.